NCT01506869

Brief Summary

Phase 1: Baseline investigation (nation-wide survey) Aims: To investigate whether diabetes and prediabetes is a risk factor for cancers of all sites as well as for specific type of cancer, such as breast and colorectal cancer. Subjects and Methods: A nation-wide survey will be carried out in 200,000-250,000 individuals selected from 20-25 communities stratified according to geographic regions (northeast, north, east, south central, northwest, and southwest China), degrees of urbanization (large cities \[Beijing, Shanghai, and provincial capitals\], midsize cities, county seats, and rural townships), and economic development status (as assessed on the basis of the gross domestic product \[GDP\] for each province). A comprehensive examination including questionnaire, anthropometric measurements, biochemical analysis will be performed in each study participant. Diabetes and prediabetes should be diagnosed by OGTT according to the WHO 1999 criteria, while the diagnosis of cancer is established on the self-report questionnaire and cross checking with the tumor registry or a proof of doctor's diagnosis. Phase 2: Cohort follow-up Aims : To examine factors that modify the risk of cancer in diabetes, prediabetes and normal glucose regulation (NGR). Subjects and Methods: To recruit and follow all type 2 diabetes, prediabetes, and sex,age-matched NGR (1:1) in each community for at least 3 years. For diabetes, treatment target is HbA1c ≤ 7.0% with treatment paradigm recommended by local guideline.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2011

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 5, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 10, 2012

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

January 10, 2012

Status Verified

January 1, 2012

Enrollment Period

3.6 years

First QC Date

January 5, 2012

Last Update Submit

January 9, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • number of participants who develop cancer during follow-up

    3 years

Study Arms (3)

Type 2 diabetes

Prediabetes

Normal glucose regulation

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

In phase 1, 200,000-250,000 individuals selected from 20-25 communities stratified according to geographic regions, degrees of urbanization, and economic development status In Phase 2, 30,000-40,000 type 2 diabetes, 20,000-30,000 prediabetes, 30,000-40,000 normal glucose regulation, recruited from the baseline survey

You may qualify if:

  • Age \>= 40 years old
  • Gender: males and females
  • Provide written informed consent
  • Satisfactory compliance
  • Phase 2
  • Age \>= 40 and =\< 75 years old
  • Gender: males and females
  • Provide written informed consent
  • Satisfactory compliance

You may not qualify if:

  • History of cancer;
  • History of LADA and other autoimmunity diseases;
  • Acute diabetic complication, acidosis, etc;
  • Moderate to severe liver, kidney dysfunction, i.e. ALT/AST \> 2.5 times the upper limit of normal range or Ccr \< 25ml/min;
  • Any other condition or major systemic diseases that the investigator feels would interfere with trial participation or evaluation of results.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Jiao-Tong University School of Medicine

Shanghai, 200025, China

RECRUITING

Related Publications (3)

  • Wang L, Wu P, Chen K, Li B, Wang J, Mu Y. Correlation between rate-pressure product or pressure-rate quotient and urinary albumin-creatinine ratio in the Chinese older population: The REACTION study. Chin Med J (Engl). 2024 Jan 20;137(2):238-240. doi: 10.1097/CM9.0000000000002941. Epub 2024 Jan 8. No abstract available.

  • Xu C, Zhou G, Zhao M, Zhang X, Fang L, Guan Q, Zhang H, Gao L, Zhang T, Zhao J. Bidirectional temporal relationship between obesity and hyperinsulinemia: longitudinal observation from a Chinese cohort. BMJ Open Diabetes Res Care. 2021 Feb;9(1):e002059. doi: 10.1136/bmjdrc-2020-002059.

  • Chen Y, Lin H, Qin L, Lu Y, Zhao L, Xia M, Jiang J, Li X, Yu C, Zong G, Zheng Y, Gao X, Su Q, Li X. Fasting Serum Fructose Levels Are Associated With Risk of Incident Type 2 Diabetes in Middle-Aged and Older Chinese Population. Diabetes Care. 2020 Sep;43(9):2217-2225. doi: 10.2337/dc19-2494. Epub 2020 Jul 1.

Biospecimen

Retention: SAMPLES WITH DNA

Blood and urine samples were collected and retained for biomarker analysis

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Guang Ning, MD,PHD

    Shanghai Jiao Tong University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 5, 2012

First Posted

January 10, 2012

Study Start

May 1, 2011

Primary Completion

December 1, 2014

Study Completion

June 1, 2015

Last Updated

January 10, 2012

Record last verified: 2012-01

Locations